# EDGAR Filing Document

**Accession Number:** 0001810747
**File Stem:** 0000940400-25-011490
**Filing Date:** 2025-11
**Character Count:** 19423
**Document Hash:** a98c23580c6b7e9bdb729f7b1c8becf1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000940400-25-011490.hdr.sgml**: 20251128

**ACCESSION NUMBER**: 0000940400-25-011490

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251128

**DATE AS OF CHANGE**: 20251128

**PERIOD START**: 20260630

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Simplify Exchange Traded Funds
- **CENTRAL INDEX KEY:** 0001810747

**ORGANIZATION NAME:**
- **EIN:** 851887571
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-23570
- **FILM NUMBER:** 251534483

**BUSINESS ADDRESS:**
- **STREET 1:** 222 BROADWAY
- **STREET 2:** 22ND FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10038
- **BUSINESS PHONE:** 646-741-2438

**MAIL ADDRESS:**
- **STREET 1:** 222 BROADWAY
- **STREET 2:** 22ND FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10038

## Series and Classes Contracts Data

### Simplify Propel Opportunities ETF (Series ID: S000078061)

| Class ID   | Class Name                        | Ticker Symbol   |
|:---|:---|:---|
| C000238807 | Simplify Propel Opportunities ETF | SURI            |

## Nport-Ex

#### Simplify

#### Propel

#### Opportunities

#### ETF

#### Schedule

#### of

#### Investments
September

30,

2025

(Unaudited)

#### Shares

#### Value

#### Common

#### Stocks

#### –

#### 59.0%

#### Health

#### Care

#### –

#### 59.0%
Abeona

Therapeutics,

Inc.\*

..................................................

558,584

$

2,949,324

Achieve

Life

Sciences,

Inc.\*

.................................................

1,184,512

3,731,213

Akero

Therapeutics,

Inc.\*

...................................................

145,609

6,913,515

Applied

Therapeutics,

Inc.\*

..................................................

4,487,505

2,714,492

Athira

Pharma,

Inc.\*

.......................................................

149,279

618,015

Celldex

Therapeutics,

Inc.\*

..................................................

85,000

2,198,950

Chinook

Therapeutics,

Inc.\*(a)

...............................................

25,000

2,500

Compass

Pathways

PLC,

ADR\*

..............................................

290,000

1,661,700

DBV

Technologies

SA\*

.....................................................

94,390

185,954

Delcath

Systems,

Inc.\*

.....................................................

261,126

2,807,104

Eiger

BioPharmaceuticals,

Inc.\*(a)

............................................

90,000

192,600

Jasper

Therapeutics,

Inc.\*

..................................................

609,053

1,449,546

Milestone

Pharmaceuticals,

Inc.\*

.............................................

2,832,974

5,665,948

Nektar

Therapeutics\*

......................................................

28,000

1,593,200

Phathom

Pharmaceuticals,

Inc.\*

..............................................

321,935

3,789,175

TScan

Therapeutics,

Inc.\*

...................................................

904,972

1,647,049

Viridian

Therapeutics,

Inc.\*

..................................................

50,000

1,079,000

WTS

-

Achieve

Life

Science,

Inc.\*(a)

..........................................

966,667

145,000

Zevra

Therapeutics,

Inc.\*

...................................................

147,000

1,397,970

Total

Common

Stocks

(Cost

$52,732,969)

..........................................

40,742,255

#### Principal

#### U.S.

#### Treasury

#### Bills

#### –

#### 46.1%
U.S.

Treasury

Bill,

4.01%,

11/18/2025

(b)(c) (Cost

$31,832,302)

......................................................

$

32,000,000

31,829,926

#### Shares

#### Limited

#### Partnership

#### –

#### 33.6%

#### Energy

#### –

#### 33.6%
Plains

GP

Holdings

LP,

Class

A\*

(Cost

$4,616,207)

.......................................................

1,272,360

23,207,847

#### Money

#### Market

#### Fund

#### –

#### 5.8%
Fidelity

Investments

Money

Market

Treasury

Only

Portfolio

-

Class

I,

4.00%(d)

(Cost

$3,982,401)

.......................................................

3,982,401

3,982,401

#### Principal

#### Corporate

#### Bonds

#### –

#### 3.1%

#### Communications

#### –

#### 3.1%
Telesat

Canada

/

Telesat

LLC,

5.63%,

12/6/2026,

144A(e)

(Cost

$2,248,840)

.......................................................

2,700,000

2,173,500

#### Shares

#### Warrants

#### –

#### 1.7%

#### –

#### 1.7%
Jasper

Therapeutics,

Inc.,

Expires

12/31/49\*(a)

..................................

609,053

–

Milestone

Pharmaeuticals,

Inc.,

Expires

7/14/30\*(a)

..............................

1,842,974

230,372

Milestone

Pharmaeuticals,

Inc.,

Expires

7/14/26\*(a)

..............................

1,842,974

921,487

Total

Warrants

(Cost

$–)

........................................................

1,151,859

#### Simplify

#### Propel

#### Opportunities

#### ETF

#### Schedule

#### of

#### Investments
(Continued)

September

30,

2025

(Unaudited)

#### Value
Total

Investments

–

149.3%

(Cost

$95,412,719)

............................................................

$

103,087,788

Liabilities

in

Excess

of

Other

Assets

–

(49.3)%

........................................

(34,017,969)

#### Net

#### Assets

#### –

#### 100.0%

#### ............................................................

#### $

#### 69,069,819
\*

Non

Income

Producing

(a) Investment

was

valued

using

significant

unobservable

inputs.

(b) Represents

a

zero

coupon

bond.

Rate

shown

reflects

the

effective

yield.

(c) Security,

or

a

portion

thereof,

in

the

amount

of

$31,829,760

has

been

pledged

as

collateral

for

reverse

repurchase

agreements

as

of

September

30,

2025. (d) Rate

shown

reflects

the

7-day

yield

as

of

September

30,

2025. (e) Security

was

purchased

(sold)

pursuant

to

Rule

144A

under

the

Securities

Act

of

1933

and

may

not

be

resold

(repurchased)

subject

to

that

rule

except

to

qualified

institutional

buyers.

Unless

otherwise

noted,

Rule

144A

securities

are

deemed

to

be

liquid.

Total

fair

value

of

Rule

144A

securities

amounts

to

$2,173,500,

which

represents

3.1%

of

net

assets

as

of

September

30,

2025. #### Abbreviations:
ADR

:

American

Depositary

Receipt

#### Summary

#### of

#### Investment

#### Type††

#### Investment

#### Categories

#### %

#### of

#### Net

#### Assets
Common

Stocks

..............................................................................

59.0%

U.S.

Treasury

Bills

.............................................................................

46.1%

Limited

Partnership

............................................................................

33.6%

Money

Market

Fund

...........................................................................

5.8%

Corporate

Bonds

..............................................................................

3.1%

Warrants

....................................................................................

1.7%

Total

Investments

.............................................................................

149.3%

Liabilities

in

Excess

of

Other

Assets

...............................................................

(49.3)%

#### Net

#### Assets

#### ..................................................................................

#### 100.0%
††

The

percentage

shown

for

each

investment

category

is

the

total

value

of

investments

in

that

category

as

a

percentage

of

the

net

assets

of

the

Fund.

The

table

depicts

the

Fund's

investments

but

may

not

represent

the

Fund's

market

exposure

to

certain

derivatives,

if

any,

which

are

included

in

Liabilities

in

Excess

of

Other

Assets.

#### At

#### September

#### 30,

#### 2025,

#### open

#### reverse

#### repurchase

#### agreements

#### were

#### as

#### follows:

#### Counterparty

#### Interest

#### Rate

#### Trade

#### Date

#### Maturity

#### Date

#### Face

#### Amount

#### Payable

#### for

#### Reverse

#### Repurchase

#### Agreements
Morgan

Stanley

Capital

Services

LLC

4.35%

9/30/2025

10/2/2025

$

31,193,583

$

31,193,583

$

31,193,583

$

31,193,583

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** Simplify Exchange Traded Funds

- **b. Investment Company Act file number:** 811-23570

- **c. CIK number of Registrant:** 0001810747

- **d. LEI of Registrant:** 549300LDDEMEUCZQEO55

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 10845 Griffith Peak Drive

  - **City:** Las Vegas

  - **State:** NV

  - **Foreign country:** US

  - **Zip / Postal Code:** 89135

  - **Telephone number:** (702) 389-9705

**Item A.2. Information about the Series.**

- **a. Name of Series:** Simplify Propel Opportunities ETF

- **b. EDGAR series identifier (if any):** S000078061

- **c. LEI of Series:** 549300DJ9GVPZFC9VR09

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-06-30

- **b. Date as of which information is reported:** 2025-09-30

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $102469095.78

**Total Liabilities:** $33383777.39

**Net Assets:** $69085318.39

**Cash Not Reported:** $17.29

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000238807 | 0.68%                | 5.57%                | 1.50%                |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $-344560.42              | $1305136.75                                |
| Month 2  | $-0.01                   | $3688114.48                                |
| Month 3  | $-733066.80              | $1791959.85                                |

**Designated Index Information**

- **Index Name:** Self Reference

- **Index Identifier:** N/A

### Schedule of Portfolio Investments

| Name                          | Title                         | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Phathom Pharmaceuticals Inc   | Phathom Pharmaceuticals Inc   | CUSIP: 71722W107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    321935 | NS      | $3789174.95   | 5.48%             |  |  |  | No            |                  1 | On Loan: No      |
| Nektar Therapeutics           | Nektar Therapeutics           | CUSIP: 640268306<br>LEI: 5299005I24806IOIYE03 | Long             | EC               | CORP              | US        |     16000 | NS      | $910400.00    | 1.32%             |  |  |  | No            |                  1 | On Loan: No      |
| Celldex Therapeutics Inc      | Celldex Therapeutics Inc      | CUSIP: 15117B202<br>LEI: 529900F018DMYWH38923 | Long             | EC               | CORP              | US        |     85000 | NS      | $2198950.00   | 3.18%             |  |  |  | No            |                  1 | On Loan: No      |
| TELESAT CANADA/TELESAT L      | Telesat Canada / Telesat LLC  | CUSIP: 87952VAR7<br>LEI: N/A                  | Long             | DBT              | CORP              | CA        |   2700000 | PA      | $2173500.00   | 3.15%             | 2026-12-06      | Fixed         | 5.62%                 | No            |                  2 | On Loan: No      |
| CHINOOK THERAPEUTICS INC CVR  | CHINOOK THERAPEUTICS INC CVR  | CUSIP: 169CVR016<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     25000 | NS      | $2500.00      | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Zevra Therapeutics Inc        | Zevra Therapeutics Inc        | CUSIP: 488445206<br>LEI: 254900CU6T74V18Y1W18 | Long             | EC               | CORP              | US        |    147000 | NS      | $1397970.00   | 2.02%             |  |  |  | No            |                  1 | On Loan: No      |
| DBV Technologies SA           | DBV Technologies SA           | CUSIP: 000000000<br>LEI: 969500PVBQFWQKVDMD80 | Long             | EC               | CORP              | FR        |     94390 | NS      | $185954.12    | 0.27%             |  |  |  | No            |                  1 | On Loan: No      |
| JASPER THERAPEUTIC WTS        | JASPER THERAPEUTIC WTS        | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    609053 | NS      | $0.00         | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Athira Pharma Inc             | Athira Pharma Inc             | CUSIP: 04746L203<br>LEI: 529900CSS4S4X8VY5C81 | Long             | EC               | CORP              | US        |    149279 | NS      | $618015.06    | 0.89%             |  |  |  | No            |                  1 | On Loan: No      |
| Compass Pathways Plc          | Compass Pathways Plc          | CUSIP: 20451W101<br>LEI: 213800N7CUZIC6QSTZ31 | Long             | EC               | CORP              | GB        |    290000 | NS      | $1661700.00   | 2.41%             |  |  |  | No            |                  1 | On Loan: No      |
| Milestone Pharmaceuticals Inc | Milestone Pharmaceuticals Inc | CUSIP: 59935V107<br>LEI: N/A                  | Long             | EC               | CORP              | CA        |   2832974 | NS      | $5665948.00   | 8.20%             |  |  |  | No            |                  1 | On Loan: No      |
| Plains GP Holdings LP         | Plains GP Holdings LP         | CUSIP: 72651A207<br>LEI: 549300O56BSKRD8FAM12 | Long             | EC               | CORP              | US        |   1272360 | NS      | $23207846.40  | 33.59%            |  |  |  | No            |                  1 | On Loan: No      |
| Viridian Therapeutics Inc     | Viridian Therapeutics Inc     | CUSIP: 92790C104<br>LEI: 549300C775BNYF550E70 | Long             | EC               | CORP              | US        |     50000 | NS      | $1079000.00   | 1.56%             |  |  |  | No            |                  1 | On Loan: No      |
| Delcath Systems Inc           | Delcath Systems Inc           | CUSIP: 24661P807<br>LEI: 549300NVPLITUM6URT02 | Long             | EC               | CORP              | US        |    261126 | NS      | $2807104.50   | 4.06%             |  |  |  | No            |                  1 | On Loan: No      |
| Abeona Therapeutics Inc       | Abeona Therapeutics Inc       | CUSIP: 00289Y206<br>LEI: 54930002Z8PIJRCB4576 | Long             | EC               | CORP              | US        |    558584 | NS      | $2949323.52   | 4.27%             |  |  |  | No            |                  1 | On Loan: No      |
| FIDELITY INV MMTRSY 1 680     | FIDELITY INV MMTRSY 1 680     | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   3982401 | NS      | $3982401.42   | 5.76%             |  |  |  | No            |                  1 | On Loan: No      |
| Akero Therapeutics Inc        | Akero Therapeutics Inc        | CUSIP: 00973Y108<br>LEI: 549300SI3KG74LBE2955 | Long             | EC               | CORP              | US        |    145609 | NS      | $6913515.32   | 10.01%            |  |  |  | No            |                  1 | On Loan: No      |
| Jasper Therapeutics Inc       | Jasper Therapeutics Inc       | CUSIP: 471871202<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    609053 | NS      | $1449546.14   | 2.10%             |  |  |  | No            |                  1 | On Loan: No      |
| TREASURY BILL                 | United States Treasury Bill   | CUSIP: 912797RP4<br>LEI: 254900HROIFWPRGM1V77 | Long             | DBT              | UST               | US        |  32000000 | PA      | $31829926.40  | 46.07%            | 2025-11-18      | None          | 0.00%                 | No            |                  1 | On Loan: No      |
| MILESTONE PHARMACE WTS        | MILESTONE PHARMACE WTS        | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1842974 | NS      | $921487.00    | 1.33%             |  |  |  | No            |                  3 | On Loan: No      |
| TScan Therapeutics Inc        | TScan Therapeutics Inc        | CUSIP: 89854M101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    904972 | NS      | $1647049.04   | 2.38%             |  |  |  | No            |                  1 | On Loan: No      |
| MILESTONE PHARMACE WTS        | MILESTONE PHARMACE WTS        | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1842974 | NS      | $230371.75    | 0.33%             |  |  |  | No            |                  3 | On Loan: No      |
| Eiger BioPharmaceuticals Inc  | Eiger BioPharmaceuticals Inc  | CUSIP: 28249U204<br>LEI: 549300GO4VMIHDKJNU46 | Long             | EC               | CORP              | US        |     90000 | NS      | $192600.00    | 0.28%             |  |  |  | No            |                  3 | On Loan: No      |
| WTS - ACHIEVE LIFE SCI        | WTS - ACHIEVE LIFE SCI        | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    966667 | NS      | $145000.05    | 0.21%             |  |  |  | No            |                  3 | On Loan: No      |
| Achieve Life Sciences Inc     | Achieve Life Sciences Inc     | CUSIP: 004468500<br>LEI: 549300V82ZKZDTAU0A46 | Long             | EC               | CORP              | US        |   1184512 | NS      | $3731212.80   | 5.40%             |  |  |  | No            |                  1 | On Loan: No      |
| Applied Therapeutics Inc      | Applied Therapeutics Inc      | CUSIP: 03828A101<br>LEI: 549300KL3IJPHZM2GR04 | Long             | EC               | CORP              | US        |   4487505 | NS      | $2714491.77   | 3.93%             |  |  |  | No            |                  1 | On Loan: No      |
| MORGAN STANLEY & CO. LLC      | Morgan Stanley                | CUSIP: 000000000<br>LEI: 9R7GPTSO7KV3UQJZQ078 | Short            | RA               | CORP              | US        | -31189582 | PA      | $-31189582.00 | -45.15%           |  |  |  | No            |                  2 | On Loan: No      |

### Signature

**Date Signed:** 2025-11-26

**Name of Applicant:** Simplify Exchange Traded Funds

**Signature:** Paul Kim

**Name of Signer:** Paul Kim

**Title:** Trustee & President